Medical School · Year 1 · Foundations · includes a quiz and discussion video

Lecture 15: Apoptosis and Cell Death

Unit 1.1: Foundations of Medicine & Medical Sciences

Learning Objectives

By the end of this lecture, students will be able to:

1. Distinguish between apoptosis, necrosis, and other forms of cell death based on morphological and molecular features
2. Describe the intrinsic (mitochondrial) and extrinsic (death receptor) pathways of apoptosis
3. Explain the roles of caspases, Bcl-2 family proteins, and IAPs in regulating apoptosis
4. Identify the physiological and pathological roles of apoptosis in development and disease
5. Explain how cancer cells evade apoptosis and therapeutic strategies to restore it
6. Describe emerging concepts in regulated necrosis and other cell death pathways

Types of Cell Death

Overview

Cell death is not merely an endpoint of injury but an essential biological process that shapes the body during development, maintains tissue homeostasis throughout life, and defends against infection and cancer. Billions of cells die every day in the human body through carefully controlled processes that remove damaged, infected, superfluous, or potentially dangerous cells. Understanding the different modes of cell death, their molecular mechanisms, and their regulation is fundamental to understanding both normal physiology and the pathophysiology of numerous diseases.

Apoptosis (Type I Cell Death)

Apoptosis, from the Greek meaning "falling off" (like leaves from a tree), is the prototypical form of programmed cell death. It is an active, energy-requiring process that follows a defined molecular program. Unlike accidental cell death from overwhelming injury, apoptosis is controlled, predictable, and non-inflammatory. The cell activates intrinsic death machinery, dismantles itself in an orderly fashion, and is quickly engulfed by neighboring cells or phagocytes without releasing its contents into the surrounding tissue.

The morphological hallmarks of apoptosis are distinctive. The cell shrinks rather than swells, its cytoplasm condenses, and the chromatin compacts against the nuclear envelope. The nucleus fragments into several pieces, each surrounded by a double membrane. The plasma membrane remains intact but undergoes dramatic blebbing—forming bubble-like protrusions that eventually pinch off as membrane-bound apoptotic bodies. These apoptotic bodies contain fragments of the cell's contents, including nuclear fragments, and are rapidly recognized and engulfed by phagocytes. A key "eat me" signal is the externalization of phosphatidylserine, a phospholipid normally restricted to the inner leaflet of the plasma membrane; its appearance on the outer surface is recognized by phagocyte receptors.

Critically, apoptosis does not trigger inflammation. The cell's contents remain membrane-enclosed throughout the process and are disposed of before they can leak out. This stands in stark contrast to necrosis, where cell contents spill into the tissue and provoke a robust inflammatory response.

Necrosis

Necrosis represents cell death from severe, overwhelming injury that exceeds the cell's capacity to mount a controlled response. Classic necrosis is considered an uncontrolled, passive process—the cell simply fails. Typical triggers include severe hypoxia, extreme temperatures, toxins, and physical trauma.

The morphology of necrosis is opposite to that of apoptosis. The cell swells (oncosis) as ion pumps fail and water enters. Organelles swell and rupture. Eventually, the plasma membrane ruptures, releasing the cell's contents into the extracellular space. These contents include damage-associated molecular patterns (DAMPs)—molecules like ATP, DNA, HMGB1, and uric acid that alert the immune system to danger. The result is inflammation, which can damage surrounding tissue even as it initiates repair processes.

<image>Panel A: Apoptosis early and intermediate stages showing cell shrinkage, chromatin condensing at nuclear periphery, membrane blebbing, and nucleus fragmenting into multiple pieces. Panel B: Apoptosis late stage showing the cell broken into multiple apoptotic bodies (small membrane-bound spheres) being engulfed by a macrophage (approaching with pseudopods), with no inflammation indicated. Panel C: Necrosis early and intermediate stages showing cell swelling, organelles becoming distended, vacuolation, and membrane integrity failing. Panel D: Necrosis late stage showing the cell ruptured with contents (red dots representing DAMPs) spilling out and inflammatory cells (neutrophils with multilobed nuclei) arriving, with a legend distinguishing features: cell shrinkage vs. swelling, membrane blebbing vs. rupture, clean phagocytosis vs. inflammation.</image>

Other Forms of Cell Death

Beyond classical apoptosis and necrosis, researchers have identified several additional regulated cell death pathways, each with distinct molecular mechanisms and physiological contexts.

Autophagy (sometimes called type II cell death) involves the cell digesting its own components through lysosomal degradation. While autophagy typically promotes survival by recycling cellular components during starvation, excessive autophagy can lead to cell death. The relationship between autophagy and cell death is complex and context-dependent.

Necroptosis is a form of programmed necrosis that combines features of both apoptosis (being regulated and programmed) and necrosis (morphological features including membrane rupture and inflammation). It is mediated by the kinases RIPK1 and RIPK3 and the pseudokinase MLKL, which permeabilizes the plasma membrane. Necroptosis serves as a backup death pathway when apoptosis is blocked (for example, by viral caspase inhibitors) and plays roles in host defense against infection.

Pyroptosis is an inflammatory form of cell death triggered by inflammasomes and executed by inflammatory caspases (caspase-1, -4, -5, and -11). These caspases cleave gasdermin D, which forms pores in the plasma membrane, releasing inflammatory cytokines IL-1β and IL-18. Pyroptosis is important for defense against intracellular pathogens.

Ferroptosis is an iron-dependent form of cell death driven by lipid peroxidation. It is morphologically and biochemically distinct from apoptosis and may contribute to neurodegenerative diseases and ischemia-reperfusion injury.

Caspases: Executioners of Apoptosis

The Caspase Family

Caspases (cysteine-aspartic proteases) are the central executioners of apoptosis. These enzymes cleave their substrates after aspartate residues using a cysteine nucleophile in their active site—hence the name "caspase." Like many proteases, caspases are synthesized as inactive zymogens (procaspases) that require proteolytic processing for activation. This ensures that these potentially lethal enzymes remain silent until deliberately activated.

Classification

Caspases fall into three functional categories. Initiator caspases (caspase-8, -9, and -10) are activated at the apex of the apoptotic cascade and function to activate downstream effector caspases. They have long prodomains containing protein-protein interaction motifs that recruit them to activation platforms. Executioner caspases (caspase-3, -6, and -7) are activated by initiator caspases and directly cleave cellular substrates to dismantle the cell. They have short prodomains and, once activated, amplify the death signal by activating additional executioner caspases. Inflammatory caspases (caspase-1, -4, -5, and -11) function in innate immunity and pyroptosis rather than classical apoptosis; they process pro-inflammatory cytokines and execute pyroptotic cell death.

Caspase Substrates

Activated executioner caspases cleave hundreds of cellular proteins, and these cleavage events produce the characteristic features of apoptotic death. PARP (poly-ADP-ribose polymerase), a DNA repair enzyme, is cleaved and inactivated—PARP cleavage is commonly used as a marker of apoptosis. Cleavage of ICAD (inhibitor of caspase-activated DNase) releases CAD, the endonuclease responsible for the internucleosomal DNA fragmentation that produces the characteristic DNA ladder visible on gel electrophoresis. Nuclear lamins are cleaved, leading to nuclear envelope breakdown. Cytoskeletal proteins are cleaved, causing cell shrinkage and membrane blebbing. In total, more than a thousand caspase substrates have been identified, and their coordinated cleavage produces the orderly demolition characteristic of apoptosis.

<image>Panel A: Two activating stimuli at the top: death receptor engagement leading to caspase-8 and mitochondrial pathway leading to caspase-9, shown as inactive procaspases becoming cleaved and active with prodomains as separate fragments. Panel B: Initiator caspases (caspase-8 and -9) activating executioner caspases (caspase-3, -6, -7), shown transitioning from inactive to active forms via proteolytic cleavage. Panel C: Active executioner caspases cleaving cellular substrates: PARP (inactivation, DNA repair blocked), ICAD (CAD released, DNA fragmentation), lamins (nuclear envelope breakdown), and cytoskeleton proteins (shrinkage, blebbing). Panel D: Morphological outcomes illustrated: DNA ladder pattern on gel electrophoresis, condensed nucleus, and membrane blebs characteristic of apoptotic cell death.</image>

The Intrinsic (Mitochondrial) Pathway

Triggers

The intrinsic pathway is activated by intracellular stress signals that indicate the cell is damaged beyond repair or has exceeded its normal lifespan. Triggers include DNA damage (from radiation, chemotherapy, or replication errors), oxidative stress (excessive reactive oxygen species), growth factor withdrawal (loss of survival signals), endoplasmic reticulum stress (accumulation of misfolded proteins), and various chemotherapeutic agents designed to exploit this pathway. All these stresses converge on the mitochondria, making mitochondrial outer membrane permeabilization (MOMP) the decisive event in the intrinsic pathway.

The Bcl-2 Family

The Bcl-2 family of proteins are the master regulators of the intrinsic pathway, controlling whether MOMP occurs. They are defined by the presence of Bcl-2 homology (BH) domains and fall into three functional subfamilies.

Anti-apoptotic members include Bcl-2 (the founding member, discovered through its involvement in follicular lymphoma), Bcl-xL, and Mcl-1. These proteins contain all four BH domains (BH1-4) and localize to the mitochondrial outer membrane, where they prevent MOMP by binding and sequestering pro-apoptotic family members.

Pro-apoptotic effector proteins include Bax and Bak. These proteins contain BH1-3 domains and, when activated, oligomerize to form pores in the mitochondrial outer membrane. Bak normally resides at mitochondria, held in check by anti-apoptotic proteins; Bax normally resides in the cytosol and translocates to mitochondria upon activation.

BH3-only proteins are the sensors that initiate the pathway in response to specific stresses. They contain only the BH3 domain and include Bid, Bim, Bad, Puma, and Noxa. Some BH3-only proteins (direct activators like Bid and Bim) can directly activate Bax and Bak. Others (sensitizers like Bad and Noxa) bind anti-apoptotic proteins and release sequestered Bax and Bak. The p53 tumor suppressor induces expression of Puma and Noxa, connecting DNA damage to apoptosis.

The Intrinsic Pathway Mechanism

When stress signals induce BH3-only proteins, the balance shifts toward death. BH3-only proteins either directly activate Bax/Bak or neutralize anti-apoptotic Bcl-2 family members that were keeping Bax/Bak in check. Activated Bax translocates to mitochondria where it and Bak oligomerize into large pores spanning the outer mitochondrial membrane.

MOMP releases several proteins from the intermembrane space into the cytosol. Most importantly, cytochrome c is released. Cytochrome c binds to Apaf-1 (apoptotic protease activating factor 1), which in the presence of dATP oligomerizes into a large wheel-shaped structure called the apoptosome. The apoptosome recruits procaspase-9 through their shared CARD (caspase recruitment domain) motifs. Procaspase-9 is activated by proximity-induced dimerization, and active caspase-9 then cleaves and activates executioner caspases-3 and -7.

Other proteins released from mitochondria amplify apoptosis. Smac/DIABLO binds and antagonizes IAPs (inhibitor of apoptosis proteins), removing their block on caspase activity. AIF (apoptosis-inducing factor) translocates to the nucleus and contributes to DNA fragmentation. MOMP is therefore the point of no return—once it occurs, the cell is committed to death.

<image>Panel A: Various stress stimuli (DNA damage as broken DNA, oxidative stress as ROS symbols, growth factor withdrawal as absent receptor signal) inducing BH3-only proteins (Puma and Noxa as p53-induced; Bad as growth factor dependent), with a balance scale depicting anti-apoptotic proteins (Bcl-2, Bcl-xL in green) versus pro-apoptotic effectors (Bax, Bak in red). Panel B: At the mitochondrion, Bax/Bak oligomerizing to form pores in the outer membrane, with cytochrome c (small orange circles) exiting through the pores into the cytoplasm. Panel C: Cytochrome c binding Apaf-1 (gray shapes) to form the wheel-shaped apoptosome with seven spokes, procaspase-9 (blue) recruited and becoming active caspase-9, which activates caspase-3/7 (yellow). Panel D: Additional mitochondrial releases: Smac/DIABLO (purple) inhibiting IAPs (pink, shown being blocked) and AIF (brown) translocating to the nucleus for DNA fragmentation.</image>

The Extrinsic (Death Receptor) Pathway

Death Receptors

The extrinsic pathway is triggered by extracellular signals—ligands binding to death receptors on the cell surface. Death receptors belong to the tumor necrosis factor (TNF) receptor superfamily and are characterized by an intracellular death domain (DD) that mediates signal transduction. Key death receptors include Fas (also called CD95 or APO-1), TNFR1 (TNF receptor 1), and TRAIL receptors DR4 and DR5 (also called TRAIL-R1 and TRAIL-R2).

Death Ligands

The corresponding death ligands are members of the TNF superfamily. FasL (Fas ligand) is expressed on activated T cells and natural killer cells, allowing them to kill target cells expressing Fas—this is the principal mechanism by which cytotoxic lymphocytes eliminate infected or cancerous cells. TNF-α is primarily a pro-inflammatory cytokine but can trigger apoptosis under certain conditions. TRAIL (TNF-related apoptosis-inducing ligand) preferentially kills cancer cells over normal cells, making it an attractive potential cancer therapy.

The Extrinsic Pathway Mechanism

When death ligands (which exist as trimers) bind their cognate receptors, the receptors trimerize, bringing their intracellular death domains into proximity. The adaptor protein FADD (Fas-associated death domain protein) is then recruited through homotypic death domain interactions. FADD also contains a death effector domain (DED) through which it recruits procaspase-8 (or procaspase-10). This assembly of receptor, FADD, and procaspase-8 is called the DISC (death-inducing signaling complex).

Procaspase-8 molecules recruited to the DISC are activated by proximity-induced dimerization—the high local concentration of procaspase-8 allows them to cleave and activate each other. Active caspase-8 then directly cleaves and activates executioner caspases-3 and -7.

In some cells (type I cells, such as thymocytes), DISC-generated caspase-8 activity is sufficient to activate enough executioner caspase for cell death. In other cells (type II cells, such as hepatocytes), the DISC signal is weaker and requires amplification. Amplification occurs through caspase-8 cleavage of Bid, a BH3-only protein. Cleaved Bid (truncated Bid, or tBid) translocates to mitochondria and activates the intrinsic pathway, leading to MOMP and apoptosome formation. Thus, in type II cells, the extrinsic pathway connects to and requires the intrinsic pathway for efficient cell death.

<image>Panel A: Cell membrane with death receptor (Fas) as a monomer on the left and as a trimerized complex on the right after FasL (trimeric ligand) binds, showing intracellular death domains (DD, purple boxes) clustered together. Panel B: DISC formation with FADD (adaptor protein with DD and DED domains) recruited via DD-DD interaction, and procaspase-8 molecules (gray shapes with DEDs) recruited via DED-DED interaction, becoming cleaved and active caspase-8. Panel C: Direct pathway (Type I cells) where caspase-8 directly activates caspase-3/7, leading to apoptosis without mitochondrial involvement. Panel D: Amplification pathway (Type II cells) where caspase-8 cleaves Bid to tBid, which translocates to mitochondria (dashed arrow) triggering MOMP and the intrinsic pathway, greatly amplifying caspase activation and converging on active caspase-3/7.</image>

Inhibitors of Apoptosis

The IAP Family

Cells maintain safeguards against inappropriate apoptosis through inhibitor of apoptosis proteins (IAPs). The best-characterized IAPs include XIAP (X-linked IAP, the most potent caspase inhibitor), cIAP1 and cIAP2 (cellular IAPs involved in TNF signaling), and survivin (important in mitosis and cancer). IAPs contain BIR (baculovirus IAP repeat) domains that mediate binding to and inhibition of caspases. XIAP directly binds and inhibits caspase-3, -7, and -9, providing a threshold that must be overcome for apoptosis to proceed.

Smac/DIABLO

The balance is restored by Smac/DIABLO, released from mitochondria along with cytochrome c during MOMP. Smac binds to IAPs and prevents them from inhibiting caspases. The interplay between IAPs and Smac establishes a threshold: low-level caspase activation (perhaps from spurious DISC formation or limited mitochondrial damage) is suppressed by IAPs, but once MOMP releases sufficient Smac, IAPs are neutralized and apoptosis proceeds. This threshold mechanism prevents apoptosis from occurring in response to minor, transient stresses while ensuring robust death when it is appropriate.

FLIP

FLIP (FLICE-inhibitory protein, where FLICE was an early name for caspase-8) inhibits the extrinsic pathway specifically. FLIP is structurally similar to caspase-8 but lacks catalytic activity. It competes with procaspase-8 for recruitment to the DISC; DISC complexes containing FLIP are less effective at activating caspase-8. Elevated FLIP expression protects cells from death receptor-induced apoptosis and is observed in various cancers.

<image>Panel A: Pro-death side of the balance/seesaw showing BH3-only proteins (Bim, Bid, Puma, Bad as red weights), activated Bax/Bak, active caspases, and Smac/DIABLO. Panel B: Pro-survival side showing anti-apoptotic Bcl-2 family (Bcl-2, Bcl-xL, Mcl-1 as green weights), IAPs (XIAP, cIAP as pink weights), and FLIP. Panel C: Balance tipping toward pro-death with the fulcrum representing the cell fate decision, resulting in apoptosis when pro-death factors predominate. Panel D: Balance tipping toward pro-survival with the cell surviving, and a caption noting that cancer cells tip the balance toward survival through overexpressing Bcl-2 and IAPs and losing p53.</image>

Physiological Roles of Apoptosis

Development

Apoptosis sculpts the body during development, removing cells that have served a transient purpose or whose death is necessary for proper morphogenesis. The separation of digits provides a dramatic example: initially, the developing hand and foot are paddle-shaped with webbing between the digits. Apoptosis of the interdigital cells creates the separated fingers and toes. Failure of this process results in syndactyly (webbed digits).

The developing nervous system produces roughly twice as many neurons as will survive to adulthood. Neurons that fail to make appropriate connections or receive insufficient neurotrophic factor support undergo apoptosis and are eliminated. This "neural Darwinism" ensures that surviving neurons are properly integrated into functional circuits.

Immune System

Apoptosis is essential for a functional, self-tolerant immune system. During T cell development in the thymus, T cells that react strongly to self-antigens are deleted by apoptosis (negative selection), preventing autoimmunity. T cells that fail to recognize self-MHC are also eliminated (death by neglect). This quality control removes potentially dangerous or useless lymphocytes.

In the periphery, activated lymphocytes must be eliminated after an infection is cleared to return the immune system to homeostasis. This contraction phase relies heavily on apoptosis. Additionally, cytotoxic T lymphocytes and natural killer cells use the extrinsic pathway (FasL-Fas interactions) to kill virus-infected cells and tumor cells.

Tissue Homeostasis

Throughout the body, apoptosis balances cell proliferation to maintain tissue mass. The intestinal epithelium turns over every few days; cells born in the crypts migrate up the villus and are shed by apoptosis at the villus tip. Similarly, the epidermis undergoes continuous renewal with keratinocytes dying as they differentiate and move toward the skin surface. This balanced turnover maintains tissue integrity while allowing constant renewal.

DNA Damage Response

Apoptosis serves as a fail-safe mechanism to eliminate cells with irreparable DNA damage that might otherwise become cancerous. When the p53 tumor suppressor detects severe DNA damage, it activates transcription of pro-apoptotic genes (particularly PUMA and NOXA), triggering the intrinsic pathway. This "genomic guardian" function of p53 is critical for cancer prevention—loss of p53 allows damaged cells to survive and proliferate.

<image>Panel A: Developmental digit formation showing a progression from paddle-shaped limb bud to apoptotic cells (small fragmented cells with condensed nuclei) appearing in interdigital regions (indicated by stars) to final separated digits. Panel B: Immune system thymic selection showing a thymus cross-section with T cells undergoing selection, where cells with excessive self-reactivity receive death signals through the Fas pathway (red X, Fas/FasL interaction) and undergo apoptosis. Panel C: Tissue homeostasis in intestinal epithelium showing a villus with cell division in the crypt at the base (mitotic figures), cells migrating up the villus (arrows), and apoptotic cells shed at the villus tip into the lumen. Panel D: Overview of the continuous balance between proliferation, migration, and programmed cell death that maintains constant tissue mass across development, immune function, and epithelial renewal.</image>

Pathological Dysregulation

Insufficient Apoptosis

When apoptosis fails to occur when it should, cells that ought to die instead survive and proliferate. Cancer represents the paradigmatic example: tumor cells evade apoptosis through mechanisms including overexpression of Bcl-2 and other anti-apoptotic proteins, loss of p53 function (present in over half of human cancers), elevated IAP expression, and reduced expression of death receptors. These alterations allow cancer cells to survive DNA damage from chemotherapy and radiation, contributing to treatment resistance.

Autoimmune diseases can result when autoreactive lymphocytes escape deletion. In autoimmune lymphoproliferative syndrome (ALPS), mutations in Fas or FasL prevent normal lymphocyte apoptosis, leading to massive lymphadenopathy and autoimmunity. More subtly, defects in apoptosis of autoreactive cells may contribute to common autoimmune diseases like systemic lupus erythematosus.

Some viruses encode anti-apoptotic proteins that block host cell death, allowing continued viral replication. Examples include the E1B protein of adenovirus (which inactivates p53) and vFLIP of Kaposi sarcoma-associated herpesvirus (which inhibits death receptor signaling).

Excessive Apoptosis

Conversely, excessive or inappropriate apoptosis causes pathological cell loss. Neurodegenerative diseases including Alzheimer disease, Parkinson disease, and Huntington disease involve progressive neuronal loss partly mediated by apoptosis. Ischemia-reperfusion injury (as in stroke or myocardial infarction) triggers apoptosis of cells in the affected territory. AIDS involves progressive loss of CD4+ T cells, partly through HIV-induced apoptosis of both infected and uninfected bystander cells. Aplastic anemia results from excessive apoptosis of hematopoietic stem cells.

Apoptosis in Cancer

Evasion of Apoptosis

Evasion of apoptosis is recognized as a hallmark of cancer. To survive and proliferate, cancer cells must overcome the apoptotic signals that normally eliminate aberrant cells. Multiple mechanisms accomplish this evasion.

Loss or mutation of p53 occurs in over half of human cancers and removes a key link between DNA damage and apoptosis. Without functional p53, cells with damaged DNA proliferate rather than die, accumulating additional mutations that drive cancer progression. Overexpression of anti-apoptotic Bcl-2 family members (particularly Bcl-2 itself, Bcl-xL, and Mcl-1) raises the threshold for MOMP, making cells resistant to apoptotic stimuli. Overexpression of IAPs (particularly XIAP and survivin) provides caspase inhibition. Downregulation of death receptors or overexpression of FLIP protects against extrinsic pathway activation, helping tumor cells evade immune surveillance.

Therapeutic Strategies

Understanding apoptosis has revealed therapeutic targets to restore death in cancer cells. BH3 mimetics are small molecules that mimic BH3-only proteins, binding anti-apoptotic Bcl-2 family members and releasing their hold on Bax and Bak. Venetoclax (ABT-199) is a selective Bcl-2 inhibitor approved for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), representing a triumph of apoptosis research translating into clinical practice.

TRAIL receptor agonists (agonistic antibodies or recombinant TRAIL) can trigger the extrinsic pathway in cancer cells that retain functional death receptor signaling. The relative selectivity of TRAIL for cancer cells over normal cells made this an attractive approach, though clinical results have been mixed.

Smac mimetics (IAP antagonists) overcome the IAP block on caspases. Several are in clinical development, often in combination with other therapies. MDM2 inhibitors (such as nutlins) prevent MDM2 from degrading p53, stabilizing wild-type p53 and restoring its ability to induce apoptosis—these are effective only in tumors retaining wild-type p53.

<image>Panel A: BH3 mimetics shown as small molecules (red diamonds labeled "venetoclax") binding to Bcl-2 (green shape) and displacing Bax/Bak to allow MOMP, with rationale to restore the intrinsic pathway. Panel B: TRAIL receptor agonists as Y-shaped antibodies binding to death receptors on the cancer cell surface, triggering the extrinsic pathway. Panel C: Smac mimetics as small molecules blocking IAPs (pink hexagons) from inhibiting caspases, with rationale to remove caspase inhibition. Panel D: MDM2 inhibitors as small molecules preventing MDM2 (black circle) from degrading p53 (brown diamond), allowing p53 to accumulate and activate pro-apoptotic genes, with rationale to reactivate the p53 tumor suppressor.</image>

Methods to Detect Apoptosis

Understanding apoptosis has enabled development of numerous assays for detecting apoptotic cells in research and clinical settings. The TUNEL assay (terminal deoxynucleotidyl transferase dUTP nick end labeling) detects the DNA fragmentation characteristic of apoptosis by labeling the 3'-OH ends of DNA breaks. Annexin V staining detects phosphatidylserine externalization—annexin V is a protein that binds phosphatidylserine, and fluorescent conjugates can identify apoptotic cells by flow cytometry or microscopy. Caspase activity assays use fluorogenic or colorimetric substrates that are cleaved by active caspases, releasing a detectable signal. Mitochondrial membrane potential assays using dyes like JC-1 or TMRE detect the loss of mitochondrial membrane potential that accompanies MOMP. Morphological assessment by microscopy can identify characteristic nuclear changes (condensation, fragmentation) in stained cells. DNA ladder assays using gel electrophoresis can detect the internucleosomal cleavage pattern (multiples of approximately 180 bp) that produces a characteristic "ladder" pattern.

Clinical Correlations

Bcl-2 and Follicular Lymphoma

The BCL2 gene was discovered through its involvement in follicular lymphoma, where the t(14;18) chromosomal translocation places BCL2 under control of the immunoglobulin heavy chain enhancer. The resulting Bcl-2 overexpression prevents normal B cell apoptosis in germinal centers, allowing accumulation of the cells that become lymphoma. This discovery established that blocking cell death—not just promoting proliferation—could drive cancer. The development of venetoclax to inhibit Bcl-2 came full circle from this discovery, providing targeted therapy for Bcl-2-dependent malignancies.

Fas Mutations and Autoimmune Lymphoproliferative Syndrome

ALPS is caused by inherited mutations in genes encoding Fas, FasL, or downstream signaling components. Defective lymphocyte apoptosis leads to massive accumulation of T and B cells, with chronic lymphadenopathy, splenomegaly, and elevated risk of lymphoma. Patients also develop autoimmune cytopenias and other autoimmune manifestations. ALPS demonstrates the essential role of the extrinsic apoptotic pathway in immune homeostasis.

Therapeutic Exploitation

The therapeutic potential of manipulating apoptosis extends beyond cancer. In transplantation and autoimmunity, inducing apoptosis of pathogenic immune cells could promote tolerance. In degenerative diseases, blocking excessive apoptosis might preserve functional cells. These concepts remain largely investigational, but they highlight how fundamental understanding of cell death mechanisms may eventually yield diverse therapeutic applications.

Summary

• Apoptosis is programmed cell death characterized by shrinkage, chromatin condensation, and apoptotic body formation
• Two main pathways: intrinsic (mitochondrial) and extrinsic (death receptor)
• Caspases are the executioners; Bcl-2 family regulates the intrinsic pathway
• Apoptosis is essential for development, immune function, and tissue homeostasis
• Cancer cells evade apoptosis through multiple mechanisms
• BH3 mimetics and other pro-apoptotic drugs are emerging cancer therapies

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown